Published on 6 Apr 2023 on Zacks via Yahoo Finance

Palisade (PALI) Enrolls First Patient in LB1148 Study in China

Palisade PALI, a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, was up almost 7% on Apr 5 as it announced that its development partner, Newsoara Biopharma, has enrolled the first patient in its ongoing phase III clinical study for LB1148 in China.

The start of patient enrollment in LB1148’s phase III clinical study is an important milestone for Palisade Bio as well as Newsoara. If successful, this could lead to the availability of LB1148 for patients in China, improving postoperative outcomes and reducing the impact of delayed return of bowel function.

LB1148 is a broad-spectrum serine protease inhibitor that aims to neutralize digestive enzymes and potentially reduce intestinal damage. The study is designed as a randomized, double-blinded, placebo-controlled clinical investigation that will enroll patients undergoing scheduled bowel resection surgery using either laparotomy or laparoscopic surgical approaches.